Early‑stage NSCLC Panel
Also known as: eNSCLC Panel
Use
The Early‑stage NSCLC Panel is a therapy‑selection panel for early‑stage non–small cell lung cancer (NSCLC), designed to detect key actionable biomarkers to inform diagnosis, therapy selection, prognosis, and clinical trial eligibility. It combines multiple modalities to provide a focused, targeted, and actionable molecular profile. Clinicians may opt out of the PD‑L1 IHC component if desired.
Special Instructions
Test may be ordered with an opt‑out of PD‑L1 22C3 (IHC). Level of service: Global. New York approved: Yes.
Limitations
The EGFR PCR component is designed to detect highly recurrent somatic mutations in exons 18 (G719X), 19 (deletions), 20 (T790M, C797S, exon 20‑Ins, S768I), and 21 (L858R, L861Q). Some less common EGFR mutations are not detectable; contact NeoGenomics client services for a full list of detectable EGFR variants.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
FFPE tissue, paraffin block preferred; alternatively, send 3 H&E slides plus 18 unstained slides cut at 4‑5 microns on positively‑charged slides; use 10% NBF fixative; do not use zinc fixative.
Storage Instructions
Use cold pack for transport, ensure cold pack is not in direct contact with specimen. NYS clients: provide date and time of collection.